The objective is to design and develop a histamine h3 receptor inverse agonist as a novel type of drug for use in the treatment of alzheimer's disease, obesity and/or epilepsy.
Development of a natural component based on clays, diatomite and seaweeds which will replace the current growth promoters and the fight against mycotoxicosis in animal feed.
Development of new products to replace the subtherapeutic use of antibiotics and alternatives to the coccidiostatics currently used in farm livestock food.
Aims at developing new families of molecules to be used for in vivo dna surgery, as a therapeutic approach to genetic and viral diseases, or to be used as industrial tools.
Combining molecular technologies which permit identification - quantification of micro-organisms without cultivation and a decision diagram suggested by hygienists, whereby emerging nosocomial pathogens could be more rapidly detected and eradicated from the health area.
Development of different dosage forms containing doxycycline alone or associated with paracetamol or others, for improving the extrinsic and intrinsic characteristics for a safe and rationale use of this antibiotic in animal health.
The project develops a new system for the automated staining of blood, bone marrow & sputum slides for haematology, bacteriology & mycobacteriology. It will be designed to answer the needs of small clinical laboratories, notably in low resource countries & in regions stricken by tuberculosis.
The aim of this project is the development of an automatic platform for processing bloodchip(r), a progenika's dna array for blood genotyping, which will allow to reduce costs and to increase traceability, efficiency and quality of the process.